Literature DB >> 15952008

[The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology].

D Wedekind1, B Bandelow.   

Abstract

Calcium channel blockers are substances used for treating high blood pressure and coronary heart disease. New medications have been developed that modulate calcium channels but also show promise in psychiatric and neurologic applications. Gabapentin and pregabalin bind to a subunit of calcium channels--the alpha2delta receptors--thereby reducing calcium influx to neurons. As a result, less glutamate is released from nerve endings that use excitatory amino acids as transmitters. This in turn reduces substance P-related activation of AMPA heteroreceptors on noradrenergic synapses, total transmitter release, and finally neuronal activity. That mechanism is the probable explanation for gabapentin's and pregabalin's usefulness in the treatment of neuropathic pain but also their possible anticonvulsive and anxiolytic effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952008     DOI: 10.1007/s00115-005-1940-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  29 in total

Review 1.  Subunit interaction sites in voltage-dependent Ca2+ channels: role in channel function.

Authors:  D Walker; M De Waard
Journal:  Trends Neurosci       Date:  1998-04       Impact factor: 13.837

2.  Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.

Authors:  H Lesser; U Sharma; L LaMoreaux; R M Poole
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

3.  Treatment of social phobia with gabapentin: a placebo-controlled study.

Authors:  A C Pande; J R Davidson; J W Jefferson; C A Janney; D J Katzelnick; R H Weisler; J H Greist; S M Sutherland
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

4.  Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones.

Authors:  K G Sutton; D J Martin; R D Pinnock; K Lee; R H Scott
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Pregabalin: a new anxiolytic.

Authors:  Bianca A Lauria-Horner; Robert B Pohl
Journal:  Expert Opin Investig Drugs       Date:  2003-04       Impact factor: 6.206

Review 6.  Pregabalin: in the treatment of painful diabetic peripheral neuropathy.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Authors:  Atul C Pande; Jerri G Crockatt; Douglas E Feltner; Carol A Janney; Ward T Smith; Richard Weisler; Peter D Londborg; Robert J Bielski; Dan L Zimbroff; Jonathan R T Davidson; Maria Liu-Dumaw
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

8.  Human neuronal voltage-dependent calcium channels: studies on subunit structure and role in channel assembly.

Authors:  P F Brust; S Simerson; A F McCue; C R Deal; S Schoonmaker; M E Williams; G Veliçelebi; E C Johnson; M M Harpold; S B Ellis
Journal:  Neuropharmacology       Date:  1993-11       Impact factor: 5.250

9.  Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

Authors:  Julio Rosenstock; Michael Tuchman; Linda LaMoreaux; Uma Sharma
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

10.  Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin.

Authors:  C P Taylor; M G Vartanian; P W Yuen; C Bigge; N Suman-Chauhan; D R Hill
Journal:  Epilepsy Res       Date:  1993-01       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.